Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.R700009200 on March 29, 2007

J. Biol. Chem., Vol. 282, Issue 21, 15319-15323, May 25, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/21/15319    most recent
R700009200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uematsu, S.
Right arrow Articles by Akira, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uematsu, S.
Right arrow Articles by Akira, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Minireview

Toll-like Receptors and Type I Interferons*

Satoshi Uematsu{ddagger} and Shizuo Akira{ddagger}§1

From the {ddagger}Department of Host Defense, Research Institute for Microbial Diseases, Osaka University and §ERATO, Japan Science and Technology Corporation, 3-1 Yamada-oka, Suita Osaka 565-0871, Japan


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 Toll-like Receptors
 TLR-mediated Type I IFN...
 Conclusion and Future...
 REFERENCES
 
Toll-like receptors (TLRs) are key molecules of the innate immune systems, which detect conserved structures found in a broad range of pathogens and trigger innate immune responses. A subset of TLRs recognizes viral components and induces antiviral responses. Whereas TLR4 recognizes viral components at the cell surface, TLR3, TLR7, TLR8, and TLR9 recognize viral nucleic acids on endosomal membrane. After ligand recognition, these members activate their intrinsic signaling pathways and induce type I interferon. In this review, we discuss the recent findings of the viral recognition by TLRs and their signaling pathways.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
Toll-like Receptors
 TLR-mediated Type I IFN...
 Conclusion and Future...
 REFERENCES
 
Type I interferon (IFN),2 which was first discovered by Isaacs and Lindenmann in 1957 (1), derives its name from a function to "interfere" in viral replication. Type I IFNs are encoded by more than 13 IFN-{alpha} subfamily genes, a single IFN-beta gene, and others, such as IFN-{omega}, -{epsilon}, and -{kappa}. Type I IFNs are the key cytokines that mediate antiviral responses. Secreted IFNs bind and activate the type I IFN receptor (a heterodimer of IFNAR1 and IFNAR2) in an autocrine and paracrine manner. This binding leads to the activation of IFN-stimulated gene factor 3 (ISGF3; a heterotrimer of signal transducer and activator of transcription 1 (STAT1), STAT2, and IFN regulatory factor 9 (IRF9)), which translocates to the nucleus and induces the transcription of hundreds of effector molecules, called IFN-inducible genes (2). These effector molecules directly influence protein synthesis, cell growth, and survival, in the process of establishing an antiviral state. In addition to the induction of effector proteins, type I IFNs also induce maturation of dendritic cells, enhance antibody responses in B cells, mediate induction of CD8+ T cell responses, and recruit lymphocytes and monocytes to inflamed sites by inducing chemokines. Thus, type I IFNs mediate both innate immune responses and the subsequent development of adaptive immunity to viruses (2).

The induction of type I IFNs is triggered by pattern recognition receptors. These receptors recognize conserved molecular patterns characteristic of microorganisms, which are not generated by the host and are essential for microbial survival. The pattern recognition receptors involved in the induction of type I IFNs are divided into two categories: Toll-like receptors (TLRs) and RIG-I-like helicases (RLHs). RLHs are expressed ubiquitously and are localized in the cytosol, where they recognize dsRNA produced upon viral infection. On the other hand, TLRs are located on cell surfaces or in endosomes, where they detect viral components or viral nucleic acid (3). Here we review the induction of type I IFNs by TLRs, especially focusing on their signaling pathways.


   Toll-like Receptors
TOP
 ABSTRACT
 INTRODUCTION
 Toll-like Receptors
TLR-mediated Type I IFN...
 Conclusion and Future...
 REFERENCES
 
TLRs, a family of evolutionarily conserved pathogen recognition receptors, play a pivotal role in innate immunity. To date, the TLR family consists of 13 mammalian members. The cytoplasmic portions of TLRs show high similarity to that of the interleukin-1 receptor (IL-1R) family and are now called the Toll/IL-1 receptor (TIR) domain. A TIR domain is required to initiate intracellular signaling. The extracellular regions of TLRs and IL-1R are markedly different. Whereas IL-1R possesses an Ig-like domain, TLRs contain leucine-rich repeats in their extracellular domains. TLRs are pattern recognition receptors that sense a wide range of microorganisms, such as bacteria, fungi, protozoa, and viruses. Each TLR has its own intrinsic signaling pathway and induces specific biological responses against microorganisms such as dendritic cell maturation, cytokine production, and the development of adaptive immunity (2).


   TLR-mediated Type I IFN Signaling Pathways
TOP
 ABSTRACT
 INTRODUCTION
 Toll-like Receptors
 TLR-mediated Type I IFN...
Conclusion and Future...
 REFERENCES
 
The activation of TLR signaling pathways originates from the cytoplasmic TIR domains. Each TLR mediates distinctive responses in association with a different combination of four TIR domain-containing adapters (MyD88, TIRAP/MAL, TRIF, and TRAM) through the homophilic interaction of TIR domains (2). The association of TLRs with MyD88, which is utilized by all TLRs except TLR3, recruits IL-1R-associated kinase (IRAK)-1 and IRAK-4 and tumor necrosis factor receptor-associated factor 6 (TRAF6). IRAK-1 and TRAF6 then dissociate from this receptor complex and associate with another complex composed of transforming growth factor-beta-activated kinase (TAK1) and TAK1-binding proteins 1 (Tab1) and 2 (Tab2). This complex formation leads to the activation of TAK1, which in turn activates the transcription factors nuclear factor-{kappa}B (NF-{kappa}B) and activator protein 1 (AP-1) through the canonical I{kappa}B kinase (IKK) complex and the mitogen-activated protein kinase pathway, respectively. The kinase activity of the IKK complex is modulated by its IKK{gamma} subunit, the transcription factor NF-{kappa}B essential modulator (NEMO). NF-{kappa}B activates multiple proinflammatory cytokine genes, including tumor necrosis factor {alpha}, IL-6, and IL-1beta. In addition to this common pathway, called a MyD88-dependent pathway (Fig. 1), some TLR family members specifically involved in virus recognition have unique signaling pathways to induce type I IFNs (2).


Figure 1
View larger version (30K):
[in this window]
[in a new window]

  		FIGURE 1.
TLR3- and TLR4-mediated signaling pathways. TLR signaling pathways originate from the cytoplasmic TIR domain. A TIR domain-containing adapter, MyD88, associates with the cytoplasmic TIR domain of TLRs and recruits IRAKs to the receptor upon ligand binding. IRAKs then activate TRAF6, leading to the activation of TAK1. TAK1 activates the IKK complex consisting of IKK{alpha}, IKKbeta, and NEMO/IKK{gamma}. The IKK complex phosphorylates I{kappa}B, resulting in nuclear translocation of NF-{kappa}B, which induces expression of inflammatory cytokines. Stimulation of macrophages and DCs with LPS and dsRNA results in the activation of IRF3 and subsequent induction of IFN-beta and IFN-inducible genes. A TIR domain-containing adapter, TRIF, is responsible for TLR3- and TLR4-mediated IRF3 activation. Additionally, TLR4 also requires another adapter, TRAM, for IRF3 activation. TRIF interacts with TBK1, IKK{iota}, RIP1, and TRAF6. IRF3 is activated by TBK1 and IKK{iota}, which catalyze IRF3 phosphorylation and stimulate its nuclear translocation and DNA binding.

 
TLR3—TLR3 recognizes a synthetic analog of viral dsRNA, polyinosinic acid-cytidylic acid (poly(I·C)), and viral dsRNAs derived from dsRNA viruses such as reovirus or ssRNA viruses such as West Nile virus, respiratory syncytial virus, and encephalomyocarditis virus (2). Although TLR3 is expressed on the cell surface of fibroblasts, it localizes to endosomes in conventional dendritic cells (cDCs), requiring acidification of vesicles for its signaling (4). The three-dimensional structure of human TLR3 leucine-rich repeat motifs demonstrated direct binding of the TLR3 ectodomain to poly(I·C) (5). TLR3 interacts with CD14 and c-Src for ligand uptake and signal transduction (6, 7).

TLR3 signaling activates the transcription factors interferon regulatory factor 3 (IRF3) and NF-{kappa}B via the adapter molecule TRIF (8, 9) (Fig. 1). TRIF interacts with noncanonical IKKs TBK1 (also called NAK or T2K) and IKK{iota} (also called IKK{epsilon}) through TRAF3 and NAK-associated protein 1 (NAP1), which mediate phosphorylation of IRF3 (10–13). Activated IRF3 translocates into the nucleus and induces expression of IFN-beta. TBK1 and, to a lesser extent, IKK{iota} are responsible for TRIF-mediated IFN-beta induction (14, 15). In addition to TBK1/IKK{iota}, phosphatidylinositol 3-kinase and its downstream kinase Akt are necessary for full activation of IRF3 (16). TRAF1 and TRAF4 interact with TRIF and negatively regulate TRIF-mediated signaling pathways (17, 18). Furthermore, IRF3 activation is negatively regulated by the peptidyl-prolyl isomerase Pin1 (19).

Receptor-interacting protein-1 (RIP1) binds the C terminus of TRIF via a Rip homotypic interaction motif and mediates the TLR3-mediated NF-{kappa}B but not IRF3 activation (20). TRAF6 binds the N terminus of TRIF and cooperatively activates NF-{kappa}B (21). Although NF-{kappa}B activation by poly(I·C) is abrogated in TRAF6-deficient fibroblasts, TRIF-mediated signaling pathways were not impaired in TRAF6-deficient macrophages (22).

TLR3 signaling was shown to promote cross-priming of T cells, a process that is necessary for the induction of virus-specific T cell responses. In mice, plasmacytoid DCs (pDCs) and CD8+ DCs appear to be the major adenomatous polyposis coli subtypes involved in priming antiviral cytotoxic T lymphocyte. When CD8+ DCs expressing high levels of TLR3 phagocytize the apoptotic bodies of virus-infected or dsRNA-loaded cells, the dsRNA in the apoptotic bodies is recognized by TLR3, triggering the maturation of immature CD8+ DCs that are required for the subsequent induction of antigen-specific CD4+ and CD8+ T cell responses. In addition, type I interferons released from virus-infected cells facilitate cross-priming (23). In contrast to RLHs, cytoplasmic receptors for dsRNA, TLR3 plays a crucial role in the cross-priming of cytotoxic T lymphocytes against viruses that do not directly infect DCs.

The functions of TLR3 have been elucidated in actual viral infections. TLR3-deficient mice showed susceptibility to mouse cytomegalovirus infection because of reduced interferon production (24). However, TLR3-deficient mice were resistant to West Nile virus infection. This ssRNA flavivirus induces inflammatory responses in a TLR3-dependent manner that trigger a breakdown of the blood-brain barrier, which subsequently results in enhanced brain infection (25). These results are quite interesting, revealing that TLR3-mediated inflammatory responses to West Nile virus contribute to pathogenesis rather than to protection.

TLR4—TLR4, the first mammalian homologue of the Drosophila Toll protein (26) recognizes lipopolysaccharide (LPS), which is a cell wall component of Gram-negative bacteria (27, 28). TLR4 recognizes not only bacterial components but also viral proteins, such as the fusion (F) protein from respiratory syncytial virus and the envelope protein of mouse mammary tumor virus (29, 30). TLR4-mutated C3H/HeJ mice are sensitive to respiratory syncytial virus infection (31).

In addition to proinflammatory signals, TLR4 possesses TRIF-mediated signaling pathways (8, 9) (Fig. 1). Unlike TLR3, this pathway requires an additional adapter molecule, TRAM (32). TRAM is localized in the plasma membrane and the Golgi apparatus, where it colocalizes with TLR4. The N terminus of TRAM has a myristoylation site, mutation of which alters its normal membrane localization and abolishes TLR4 signaling, suggesting that TRAM acts as a bridging adapter between TLR4 and TRIF (33). It has also been reported that phosphorylation of TRAM by PKC{epsilon} is crucial for the activation of IRF3 and the induction of IFN-inducible genes (34).


Figure 2
View larger version (27K):
[in this window]
[in a new window]

  		FIGURE 2.
TLR9-mediated type I IFN induction in pDCs and cDCs. pDCs express TLR7 (also TLR8 in humans) and TLR9 and secrete large amounts of IFNs-{alpha} and IFN-beta in response to ssRNA and CpG DNA. This induction by TLR7 and TLR9 depends entirely on MyD88. After stimulation, IRF7 translocates into the nucleus to induce the expression of type I IFNs. IRF7 is activated through forming a signaling complex with MyD88, IRAKs, and TRAF6 in the cytoplasm. IKK{alpha}, TRAF3, and osteopontin are also involved in the activation of IRF7. cDCs also induce IFN-beta in response to TLR9 ligand. However, IRF1, but not IRF7, is responsible for the induction.

 
TRIF is also required for the induction of inflammatory cytokines in the TLR4 signaling pathway (8, 9). Similar to TLR3 signaling, TRAF6 and RIP1 bind to TRIF and are involved in TLR4-mediated NF-{kappa}B activation (20, 21). However, cells doubly deficient in TRAF6 and MyD88 still show partially activated NF-{kappa}B in response to LPS, suggesting that TRIF activates NF-{kappa}B through both TRAF6-dependent and -independent pathways of TLR4 signaling (22, 35). Although responses to LPS were normal in the absence of RIP1, LPS fails to stimulate NF-{kappa}B activation in rip –/– MyD88 –/– cells, revealing that RIP1 is required for the TRIF-dependent TLR4-induced NF-{kappa}B pathway (20).

Specific Pathways in pDCs—pDCs are specialized for producing large amounts of type I IFNs during most viral infections (36). Whereas conventional DCs (cDCs) preferentially express TLR3, TLR8, and low levels of TLR2 and TLR4, pDCs express high levels of TLR7 and TLR9 in humans. Bacterial DNA, which contains unmethylated CpG motifs, is a strong activator of host immunity. In vertebrates, the frequency of CpG motifs is remarkably reduced, and the cysteine residues of CpG motifs are highly methylated, leading to abrogation of immunostimulatory activity. TLR9 mediates the recognition of CpG DNA (37). CpG DNA motifs are also found in the genomes of DNA viruses. Mouse pDCs produce IFN-{alpha} by recognizing the CpG-containing DNA of herpes simplex virus type 2 (HSV-2) via TLR9 (38). TLR9-deficient mice were also shown to be susceptible to mouse cytomegalovirus infection, suggesting that TLR9 induces antiviral responses by sensing the CpG-containing DNA of DNA viruses (24, 39, 40).

TLR7 and TLR8 are structurally highly conserved proteins (2). The synthetic imidazoquinoline-like molecules imiquimod (R837) and resiquimod (R848) have potent antiviral activities and are used clinically for the treatment of viral infections. Murine TLR7 and human TLR7 and TLR8 recognize imidazoquinoline compounds (41, 42). Furthermore, murine TLR7 has been shown to recognize guanosine analogs such as loxoribine, which has antiviral and anti-tumor activities (2). Recently, TLR7 and human TLR8 have been shown to recognize guanosine- or uridine-rich ssRNA from viruses such as human immunodeficiency virus, vesicular stomatitis virus, and influenza virus (43, 44).

The induction of type I IFNs by TLR7 and TLR9 depends entirely on MyD88 in pDCs (45) (Fig. 2). IRF7 is a transcription factor that is structurally related to IRF3 and is expressed constitutively in pDCs. IRF7 forms a signaling complex with MyD88 and TRAF6 in the cytoplasm (46, 47). In this complex, TRAF6 activates IRF7 through its ubiquitin E3 ligase activity (46). After ligand stimulation, IRF7 is activated by its phosphorylation in TBK1/IKK{iota}-independent manner and translocates into the nucleus to induce the expression of type I IFNs (46–48). Mouse pDCs lacking IRAK-4 fail to produce both inflammatory cytokines and IFNs-{alpha} (47). Human TLR7-, TLR8-, and TLR9-mediated induction of IFN-{alpha}/beta and IFN-{lambda} was also IRAK-4-dependent (49). In mice, IRAK-1 has been shown to serve as an IRF7 kinase. IRF7 activation by TLR9 ligand is impaired in IRAK-1-deficient mice, despite normal NF-{kappa}B activation. IRAK-1, but not IRAK-4, can directly bind and phosphorylate IRF7; thus, IRAK-1 specifically mediates IFN-{alpha} induction downstream of MyD88 and IRAK-4 (50). In addition to IRAKs, IKK{alpha} has been shown to be essential for the phosphorylation of IRF7, suggesting that the IRAK-4/IRAK-1/IKK{alpha} kinase cascade might lead to the full activation of IRF7 (51). To elucidate the mechanism of IRF7 phosphorylation more precisely, analysis of mice expressing kinase-negative mutants of these molecules will be necessary in the near future. Recently, TRAF3 and osteopontin have also been shown to be involved in this signaling pathway (10, 11, 52).

The TLR9 ligands, CpG DNA, are divided into at least three distinct classes with different biological effects (53). Conventional CpG DNA, also called K/B-type CpG DNA, has a potency to activate B cells and induces inflammatory cytokines from macrophages. D/A-type CpG DNA shows a weaker activity on B cells or macrophages but induces robust production of type I IFNs from pDCs. In addition, C-type CpG DNA mediates the induction of type I IFNs, as well as B cell activation, but its potency in both effects is moderate (54). It remains unknown how different TLR9 agonists lead to such distinct outcomes. The importance of prolonged localization of a TLR9 ligand in an endosome has been suggested (55). K/B-type CpG DNA is rapidly transferred and degraded in the lysosome, whereas D/A-type CpG DNA is retained in the endosomes of pDCs. These results suggest that the endosomal retention of ligands in pDCs probably provides a platform for the interactions of signal-transducing molecules such as MyD88 and IRF7. However, this hypothesis does not fully explain the ligand specificity. If the endosomal retention of a ligand enhances its signaling, it is easy to assume that D/A-type CpG DNA induces robust production of inflammatory cytokines as well as IFN-{alpha}. As is generally known, D/A-type CpG DNA shows lower efficacy in the induction of proinflammatory cytokines than K/B-type CpG DNA. Furthermore, K/B-type CpG DNA even induces a certain amount of IFN-{alpha} from pDCs at lower concentrations (45). In IRAK-1-deficient pDCs, both K/B-type- and A/D-type-mediated IFN-{alpha} induction was severely impaired (50), suggesting that an additional mechanism exists to determine the distinct response to each type of CpG DNA.

K/B-type CpG DNA-mediated IFN-beta Induction in cDCs—Granulocyte macrophage-colony-stimulating factor-induced DCs produce a small amount of IFN-beta, but not IFN-{alpha}, in response to K/B-type CpG DNA (45). Neither IRF7 nor IRF3 is essential for this signaling pathway (56) (Fig. 2). A recent report showed that IRF1 specifically participates in induction of the IFN-beta gene in this signaling pathway. IRF1 is induced by IFN-{gamma} stimulation. After ligand stimulation, IRF1 interacts with MyD88, is activated by an unknown mechanism, and translocates into the nucleus to induce the expression of IFN-beta, inducible nitric-oxide synthase, and IL-12 p35 (56). Furthermore, IRF1 is not essential for the TRIF-dependent pathway or the TLR9-mediated pathway in pDCs. Thus, the induction of type I IFNs by CpG DNA is quite distinct between cDCs and pDCs.


   Conclusion and Future Perspectives
TOP
 ABSTRACT
 INTRODUCTION
 Toll-like Receptors
 TLR-mediated Type I IFN...
 Conclusion and Future...
REFERENCES
 
The study of innate immunity has progressed rapidly over the last decade. TLR family members, which were initially considered to be receptors for bacterial components, have been shown to be involved in viral recognition and subsequent induction of type I IFNs, which are the most important antiviral agents. Simultaneously, pDCs have been identified as professional interferon-producing cells, which play crucial roles during viral infection. It has become clear that TLRs are the major receptors for the initiation of type I IFN production in pDCs (57). In the process of these studies, evidence has been obtained that non-professional interferon-producing cells, such as cDCs and epithelial cells, can produce type I IFNs in a TLR-independent manner. All of these results led to the discovery of RLH family members, the functions and signaling pathways of which are currently among the hottest topics in immunology. Although antiviral responses have been well clarified at the cellular level, it remains unknown when, how, and in what kind of cells TLR and RLH systems are used to exclude viruses. It will be necessary to examine the functions of TLRs and RLHs dynamically by using various viral infection models in the future.


   FOOTNOTES
 
* This minireview will be reprinted in the 2007 Minireview Compendium, which will be available in January, 2008. This is the second article of three in the Innate Immunity Minireview Series. Back

1 To whom correspondence should be addressed. Tel.: 81-6-6879-8303; Fax: 81-6-6879-8305; E-mail: sakira{at}biken.osaka-u.ac.jp.

2 The abbreviations used are: IFN, interferon; IRF, IFN regulatory factor; RLH, RIG-I-like helicase; TLR, Toll-like receptor; ds, double-stranded; ss, single-stranded; TIR, Toll/IL-1 receptor; IL, interleukin; IRAK, IL-1R-associated kinase; TRAF, tumor necrosis factor receptor-associated factor; TAK, transforming growth factor-beta-activated kinase; NEMO, NF-{kappa}B essential modulator; IKK, I{kappa}B kinase; cDC, conventional dendritic cell; pDC, plasmacytoid dendritic cell; RIP, receptor-interacting protein; LPS, lipopolysaccharide. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 Toll-like Receptors
 TLR-mediated Type I IFN...
 Conclusion and Future...
 REFERENCES
 

  1. Isaacs, A., and Lindenmann, J. (1957) Proc. R. Soc. Lond. B Biol. Sci. 147, 258–267[Medline] [Order article via Infotrieve]
  2. Akira, S., Uematsu, S., and Takeuchi, O. (2006) Cell 124, 783–801[CrossRef][Medline] [Order article via Infotrieve]
  3. Kawai, T., and Akira, S. (2006) Nat. Immunol. 7, 131–137[CrossRef][Medline] [Order article via Infotrieve]
  4. Matsumoto, M., Funami, K., Tanabe, M., Oshiumi, H., Shingai, M., Seto, Y., Yamamoto, A., and Seya, T. (2003) J. Immunol. 171, 3154–3162[Abstract/Free Full Text]
  5. Choe, J., Kelker, M. S., and Wilson, I. A. (2005) Science 309, 581–585[Abstract/Free Full Text]
  6. Lee, H. K., Dunzendorfer, S., Soldau, K., and Tobias, P. S. (2006) Immunity 24, 153–163[CrossRef][Medline] [Order article via Infotrieve]
  7. Johnsen, I. B., Nguyen, T. T., Ringdal, M., Tryggestad, A. M., Bakke, O., Lien, E., Espevik, T., and Anthonsen, M. W. (2006) EMBO J. 25, 3335–3346[CrossRef][Medline] [Order article via Infotrieve]
  8. Yamamoto, M., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Sanjo, H., Takeuchi, O., Sugiyama, M., Okabe, M., Takeda, K., and Akira, S. (2003) Science 301, 640–643[Abstract/Free Full Text]
  9. Hoebe, K., Du, X., Georgel, P., Janssen, E., Tabeta, K., Kim, S. O., Goode, J., Lin, P., Mann, N., Mudd, S., Crozat, K., Sovath, S., Han, J., and Beutler, B. (2003) Nature 424, 743–748[CrossRef][Medline] [Order article via Infotrieve]
  10. Oganesyan, G., Saha, S. K., Guo, B., He, J. Q., Shahangian, A., Zarnegar, B., Perry, A., and Cheng, G. (2006) Nature 439, 208–211[CrossRef][Medline] [Order article via Infotrieve]
  11. Hacker, H., Redecke, V., Blagoev, B., Kratchmarova, I., Hsu, L. C., Wang, G. G., Kamps, M. P., Raz, E., Wagner, H., Hacker, G., Mann, M., and Karin, M. (2006) Nature 439, 204–207[CrossRef][Medline] [Order article via Infotrieve]
  12. Sasai, M., Oshiumi, H., Matsumoto, M., Inoue, N., Fujita, F., Nakanishi, M., and Seya, T. (2005) J. Immunol. 174, 27–30[Abstract/Free Full Text]
  13. Sharma, S., tenOever, B. R., Grandvaux, N., Zhou, G. P., Lin, R., and Hiscott, J. (2003) Science 300, 1148–1151[Abstract/Free Full Text]
  14. Hemmi, H., Takeuchi, O., Sato, S., Yamamoto, M., Kaisho, T., Sanjo, H., Kawai, T., Hoshino, K., Takeda, K., and Akira, S. (2004) J. Exp. Med. 199, 1641–1650[Abstract/Free Full Text]
  15. Perry, A. K., Chow, E. K., Goodnough, J. B., Yeh, W. C., and Cheng, G. (2004) J. Exp. Med. 199, 1651–1658[Abstract/Free Full Text]
  16. Sarkar, S. N., Peters, K. L., Elco, C. P., Sakamoto, S., Pal, S., and Sen, G. C. (2004) Nat. Struct. Mol. Biol. 11, 1060–1067[CrossRef][Medline] [Order article via Infotrieve]
  17. Su, X., Li, S., Meng, M., Qian, W., Xie, W., Chen, D., Zhai, Z., and Shu, H. B. (2006) Eur. J. Immunol. 36, 199–206[CrossRef][Medline] [Order article via Infotrieve]
  18. Takeshita, F., Ishii, K. J., Kobiyama, K., Kojima, Y., Coban, C., Sasaki, S., Ishii, N., Klinman, D. M., Okuda, K., Akira, S., and Suzuki, K. (2005) Eur. J. Immunol. 35, 2477–2485[CrossRef][Medline] [Order article via Infotrieve]
  19. Saitoh, T., Tun-Kyi, A., Ryo, A., Yamamoto, M., Finn, G., Fujita, T., Akira, S., Yamamoto, N., Lu, K. P., and Yamaoka, S. (2006) Nat. Immunol. 7, 598–605[CrossRef][Medline] [Order article via Infotrieve]
  20. Meylan, E., Burns, K., Hofmann, K., Blancheteau, V., Martinon, F., Kelliher, M., and Tschopp, J. (2004) Nat. Immunol. 5, 503–507[CrossRef][Medline] [Order article via Infotrieve]
  21. Sato, S., Sugiyama, M., Yamamoto, M., Watanabe, Y., Kawai, T., Takeda, K., and Akira, S. (2003) J. Immunol. 171, 4304–4310[Abstract/Free Full Text]
  22. Gohda, J., Matsumura, T., and Inoue, J. (2004) J. Immunol. 173, 2913–2917[Abstract/Free Full Text]
  23. Schulz, O., Diebold, S. S., Chen, M., Naslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y. T., Flavell, R. A., Liljestrom, P., and Reis e Sousa, C. (2005) Nature 433, 887–892[CrossRef][Medline] [Order article via Infotrieve]
  24. Tabeta, K., Georgel, P., Janssen, E., Du, X., Hoebe, K., Crozat, K., Mudd, S., Shamel, L., Sovath, S., Goode, J., Alexopoulou, L., Flavell, R. A., and Beutler, B. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 3516–3521[Abstract/Free Full Text]
  25. Wang, T., Town, T., Alexopoulou, L., Anderson, J. F., Fikrig, E., and Flavell, R. A. (2004) Nat. Med. 10, 1366–1373[CrossRef][Medline] [Order article via Infotrieve]
  26. Medzhitov, R., Preston-Hurlburt, P., and Janeway, C. J. (1997) Nature 388, 394–397[CrossRef][Medline] [Order article via Infotrieve]
  27. Poltorak, A., He, X., Smirnova, I., Liu, M. Y., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., Freudenberg, M., Ricciardi-Castagnoli, P., Layton, B., and Beutler, B. (1998) Science 282, 2085–2088[Abstract/Free Full Text]
  28. Hoshino, K., Takeuchi, O., Kawai, T., Sanjo, H., Ogawa, T., Takeda, Y., Takeda, K., and Akira, S. (1999) J. Immunol. 162, 3749–3752[Abstract/Free Full Text]
  29. Kurt-Jones, E. A., Popova, L., Kwinn, L., Haynes, L. M., Jones, L. P., Tripp, R. A., Walsh, E. E., Freeman, M. W., Golenbock, D. T., Anderson, L. J., and Finberg, R. W. (2000) Nat. Immunol. 1, 398–401[CrossRef][Medline] [Order article via Infotrieve]
  30. Rassa, J. C., Meyers, J. L., Zhang, Y., Kudaravalli, R., and Ross, S. R. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 2281–2286[Abstract/Free Full Text]
  31. Haynes, L. M., Moore, D. D., Kurt-Jones, E. A., Finberg, R. W., Anderson, L. J., and Tripp, R. A. (2001) J. Virol. 75, 10730–10737[Abstract/Free Full Text]
  32. Yamamoto, M., Sato, S., Hemmi, H., Uematsu, S., Hoshino, K., Kaisho, T., Takeuchi, O., Takeda, K., and Akira, S. (2003) Nat. Immunol. 4, 1144–1150[CrossRef][Medline] [Order article via Infotrieve]
  33. Rowe, D. C., McGettrick, A. F., Latz, E., Monks, B. G., Gay, N. J., Yamamoto, M., Akira, S., O'Neill, L. A., Fitzgerald, K. A., and Golenbock, D. T. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 6299–6304[Abstract/Free Full Text]
  34. McGettrick, A. F., Brint, E. K., Palsson-McDermott, E. M., Rowe, D. C., Golenbock, D. T., Gay, N. J., Fitzgerald, K. A., and O'Neill, L. A. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 9196–9201[Abstract/Free Full Text]
  35. Kawai, T., Takeuchi, O., Fujita, T., Inoue, J., Muhlradt, P. F., Sato, S., Hoshino, K., and Akira, S. (2001) J. Immunol. 167, 5887–5894[Abstract/Free Full Text]
  36. Liu, Y. J. (2005) Annu. Rev. Immunol. 23, 275–306[CrossRef][Medline] [Order article via Infotrieve]
  37. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S. (2000) Nature 408, 740–745[CrossRef][Medline] [Order article via Infotrieve]
  38. Lund, J., Sato, A., Akira, S., Medzhitov, R., and Iwasaki, A. (2003) J. Exp. Med. 198, 513–520[Abstract/Free Full Text]
  39. Krug, A., French, A. R., Barchet, W., Fischer, J. A., Dzionek, A., Pingel, J. T., Orihuela, M. M., Akira, S., Yokoyama, W. M., and Colonna, M. (2004) Immunity 21, 107–119[CrossRef][Medline] [Order article via Infotrieve]
  40. Krug, A., Luker, G. D., Barchet, W., Leib, D. A., Akira, S., and Colonna, M. (2004) Blood 103, 1433–1437[Abstract/Free Full Text]
  41. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., and Akira, S. (2002) Nat. Immunol. 3, 196–200[CrossRef][Medline] [Order article via Infotrieve]
  42. Ito, T., Amakawa, R., Kaisho, T., Hemmi, H., Tajima, K., Uehira, K., Ozaki, Y., Tomizawa, H., Akira, S., and Fukuhara, S. (2002) J. Exp. Med. 195, 1507–1512[Abstract/Free Full Text]
  43. Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., Reis, E., and Sousa, C. (2004) Science 303, 1529–1531[Abstract/Free Full Text]
  44. Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., and Bauer, S. (2004) Science 303, 1526–1529[Abstract/Free Full Text]
  45. Hemmi, H., Kaisho, T., Takeda, K., and Akira, S. (2003) J. Immunol. 170, 3059–3064[Abstract/Free Full Text]
  46. Kawai, T., Sato, S., Ishii, K. J., Coban, C., Hemmi, H., Yamamoto, M., Terai, K., Matsuda, M., Inoue, J., Uematsu, S., Takeuchi, O., and Akira, S. (2004) Nat. Immunol. 5, 1061–1068[CrossRef][Medline] [Order article via Infotrieve]
  47. Honda, K., Yanai, H., Mizutani, T., Negishi, H., Shimada, N., Suzuki, N., Ohba, Y., Takaoka, A., Yeh, W. C., and Taniguchi, T. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 15416–15421[Abstract/Free Full Text]
  48. Matsui, K., Kumagai, Y., Kato, H., Sato, S., Kawagoe, T., Uematsu, S., Takeuchi, O., and Akira, S. (2006) J. Immunol. 177, 5785–5789[Abstract/Free Full Text]
  49. Yang, K., Puel, A., Zhang, S., Eidenschenk, C., Ku, C. L., Casrouge, A., Picard, C., von Bernuth, H., Senechal, B., Plancoulaine, S., Al-Hajjar, S., Al-Ghonaium, A., Marodi, L., Davidson, D., Speert, D., Roifman, C., Garty, B. Z., Ozinsky, A., Barrat, F. J., Coffman, R. L., Miller, R. L., Li, X., Lebon, P., Rodriguez-Gallego, C., Chapel, H., Geissmann, F., Jouanguy, E., and Casanova, J. L. (2005) Immunity 23, 465–478[CrossRef][Medline] [Order article via Infotrieve]
  50. Uematsu, S., Sato, S., Yamamoto, M., Hirotani, T., Kato, H., Takeshita, F., Matsuda, M., Coban, C., Ishii, K. J., Kawai, T., Takeuchi, O., and Akira, S. (2005) J. Exp. Med. 201, 915–923[Abstract/Free Full Text]
  51. Hoshino, K., Sugiyama, T., Matsumoto, M., Tanaka, T., Saito, M., Hemmi, H., Ohara, O., Akira, S., and Kaisho, T. (2006) Nature 440, 949–953[CrossRef][Medline] [Order article via Infotrieve]
  52. Shinohara, M. L., Lu, L., Bu, J., Werneck, M. B., Kobayashi, K. S., Glimcher, L. H., and Cantor, H. (2006) Nat. Immunol. 7, 498–506[CrossRef][Medline] [Order article via Infotrieve]
  53. Klinman, D. M. (2004) Nat. Rev. Immunol. 4, 249–258[CrossRef][Medline] [Order article via Infotrieve]
  54. Ishii, K. J., and Akira, S. (2006) Trends Immunol. 27, 525–532[CrossRef][Medline] [Order article via Infotrieve]
  55. Honda, K., Ohba, Y., Yanai, H., Negishi, H., Mizutani, T., Takaoka, A., Taya, C., and Taniguchi, T. (2005) Nature 434, 1035–1040[CrossRef][Medline] [Order article via Infotrieve]
  56. Negishi, H., Fujita, Y., Yanai, H., Sakaguchi, S., Ouyang, X., Shinohara, M., Takayanagi, H., Ohba, Y., Taniguchi, T., and Honda, K. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 15136–15141[Abstract/Free Full Text]
  57. Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K., Tsujimura, T., Takeda, K., Fujita, T., Takeuchi, O., and Akira, S. (2005) Immunity 23, 19–28[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
A. F. de Vos, J. M. Pater, P. S. van den Pangaart, M. D. de Kruif, C. van 't Veer, and T. van der Poll
In Vivo Lipopolysaccharide Exposure of Human Blood Leukocytes Induces Cross-Tolerance to Multiple TLR Ligands
J. Immunol., July 1, 2009; 183(1): 533 - 542.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
C. D. Sadik, M. Bachmann, J. Pfeilschifter, and H. Muhl
Activation of interferon regulatory factor-3 via toll-like receptor 3 and immunomodulatory functions detected in A549 lung epithelial cells exposed to misplaced U1-snRNA
Nucleic Acids Res., June 18, 2009; (2009) gkp525v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
P. Zhang, J. O. Langland, B. L. Jacobs, and C. E. Samuel
Protein Kinase PKR-Dependent Activation of Mitogen-Activated Protein Kinases Occurs through Mitochondrial Adapter IPS-1 and Is Antagonized by Vaccinia Virus E3L
J. Virol., June 1, 2009; 83(11): 5718 - 5725.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
E. Larrea, R. Aldabe, I. Gonzalez, V. Segura, P. Sarobe, I. Echeverria, and J. Prieto
Oncostatin M Enhances the Antiviral Effects of Type I Interferon and Activates Immunostimulatory Functions in Liver Epithelial Cells
J. Virol., April 1, 2009; 83(7): 3298 - 3311.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Richter, M. H. S. Juan, J. Will, R. P. Brandes, U. Kalinke, S. Akira, J. M. Pfeilschifter, M. Hultqvist, R. Holmdahl, and H. H. Radeke
Ncf1 Provides a Reactive Oxygen Species-Independent Negative Feedback Regulation of TLR9-Induced IL-12p70 in Murine Dendritic Cells
J. Immunol., April 1, 2009; 182(7): 4183 - 4191.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. M. Sly, M. J. Hamilton, E. Kuroda, V. W. Ho, F. L. Antignano, S. L. Omeis, C. J. van Netten-Thomas, D. Wong, H. K. Brugger, O. Williams, et al.
SHIP prevents lipopolysaccharide from triggering an antiviral response in mice
Blood, March 26, 2009; 113(13): 2945 - 2954.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Yang, H.-X. Shi, X.-Y. Liu, Y.-F. Shan, B. Wei, S. Chen, and C. Wang
TRIM21 Is Essential to Sustain IFN Regulatory Factor 3 Activation during Antiviral Response
J. Immunol., March 15, 2009; 182(6): 3782 - 3792.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. S. McAllister and C. E. Samuel
The RNA-activated Protein Kinase Enhances the Induction of Interferon-{beta} and Apoptosis Mediated by Cytoplasmic RNA Sensors
J. Biol. Chem., January 16, 2009; 284(3): 1644 - 1651.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
O. Sandanger, L. Ryan, J. Bohnhorst, A.-C. Iversen, H. Husebye, O. Halaas, L. Landro, P. Aukrust, S. S. Froland, G. Elson, et al.
IL-10 Enhances MD-2 and CD14 Expression in Monocytes and the Proteins Are Increased and Correlated in HIV-Infected Patients
J. Immunol., January 1, 2009; 182(1): 588 - 595.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. K. Pfaller and K.-K. Conzelmann
Measles Virus V Protein Is a Decoy Substrate for I{kappa}B Kinase {alpha} and Prevents Toll-Like Receptor 7/9-Mediated Interferon Induction
J. Virol., December 15, 2008; 82(24): 12365 - 12373.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Zhang and C. E. Samuel
Induction of Protein Kinase PKR-dependent Activation of Interferon Regulatory Factor 3 by Vaccinia Virus Occurs through Adapter IPS-1 Signaling
J. Biol. Chem., December 12, 2008; 283(50): 34580 - 34587.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Daffis, M. A. Samuel, M. S. Suthar, M. Gale Jr., and M. S. Diamond
Toll-Like Receptor 3 Has a Protective Role against West Nile Virus Infection
J. Virol., November 1, 2008; 82(21): 10349 - 10358.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Ning, A. D. Campos, B. G. Darnay, G. L. Bentz, and J. S. Pagano
TRAF6 and the Three C-Terminal Lysine Sites on IRF7 Are Required for Its Ubiquitination-Mediated Activation by the Tumor Necrosis Factor Receptor Family Member Latent Membrane Protein 1
Mol. Cell. Biol., October 15, 2008; 28(20): 6536 - 6546.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. Le Tortorec, H. Denis, A-P. Satie, J-J. Patard, A. Ruffault, B. Jegou, and N. Dejucq-Rainsford
Antiviral responses of human Leydig cells to mumps virus infection or poly I:C stimulation
Hum. Reprod., September 1, 2008; 23(9): 2095 - 2103.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
E. M. Pietras and G. Cheng
A New TRADDition in Intracellular Antiviral Signaling
Sci. Signal., July 29, 2008; 1(30): pe36 - pe36.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Zeng, H. Li, Y. Liu, Z. Zhang, Y. Zhang, and R. Yang
Tumor-Induced Suppressor of Cytokine Signaling 3 Inhibits Toll-like Receptor 3 Signaling in Dendritic Cells via Binding to Tyrosine Kinase 2
Cancer Res., July 1, 2008; 68(13): 5397 - 5404.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
T. Hayashi, H. B. Cottam, M. Chan, G. Jin, R. I. Tawatao, B. Crain, L. Ronacher, K. Messer, D. A. Carson, and M. Corr
Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R123 - R132.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
R. Ovstebo, O. K. Olstad, B. Brusletto, A. S. Moller, A. Aase, K. B. F. Haug, P. Brandtzaeg, and P. Kierulf
Identification of Genes Particularly Sensitive to Lipopolysaccharide (LPS) in Human Monocytes Induced by Wild-Type versus LPS-Deficient Neisseria meningitidis Strains
Infect. Immun., June 1, 2008; 76(6): 2685 - 2695.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
Z. G. Ramirez-Ortiz, C. A. Specht, J. P. Wang, C. K. Lee, D. C. Bartholomeu, R. T. Gazzinelli, and S. M. Levitz
Toll-Like Receptor 9-Dependent Immune Activation by Unmethylated CpG Motifs in Aspergillus fumigatus DNA
Infect. Immun., May 1, 2008; 76(5): 2123 - 2129.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. J. Kang, J. Chen, M. Otsuka, J. Mols, S. Ren, Y. Wang, and J. Han
Macrophage Deletion of p38{alpha} Partially Impairs Lipopolysaccharide-Induced Cellular Activation
J. Immunol., April 1, 2008; 180(7): 5075 - 5082.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Marafioti, J. C. Paterson, E. Ballabio, K. K. Reichard, S. Tedoldi, K. Hollowood, M. Dictor, M.-L. Hansmann, S. A. Pileri, M. J. Dyer, et al.
Novel markers of normal and neoplastic human plasmacytoid dendritic cells
Blood, April 1, 2008; 111(7): 3778 - 3792.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. D. Behrens, W. M. Wagner, C. J. Krco, C. L. Erskine, K. R. Kalli, J. Krempski, E. A. Gad, M. L. Disis, and K. L. Knutson
The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity
Blood, February 1, 2008; 111(3): 1472 - 1479.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. E. Samuel
Interferons, Interferon Receptors, Signal Transducer and Transcriptional Activators, and Interferon Regulatory Factors
J. Biol. Chem., July 13, 2007; 282(28): 20045 - 20046.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/21/15319    most recent
R700009200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uematsu, S.
Right arrow Articles by Akira, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uematsu, S.
Right arrow Articles by Akira, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement